NR1H3 and steatosis: In contrast, cell treatment with an LXR-α agonist (T0901317) increased the number of LDs and the expression of lipogenic genes, suggesting that FAdV-4-induced steatosis involves the activation of the LXR-α signaling pathway (Table 2) [125].